Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Kineta (KA) has shared an update.
Kineta, Inc. has shared exciting news in their latest press release about the progress of their VISTA-101 Phase 1/2 clinical trial. Their innovative immunotherapy treatment, KVA12123, is currently being tested on patients with advanced solid tumors. This update marks a significant milestone for the company and holds potential implications for the future of cancer treatment.
See more data about KA stock on TipRanks’ Stock Analysis page.
